1. Introduction {#s0005}
===============

Maple syrup urine disease (MSUD, OMIM \#[248600](248600){#ir0005}) is an autosomal recessive inherited metabolic disorder, caused by the impaired function of branched-chain α-ketoacidehydrogenase (BCKDH) complex \[[@bb0005]\]. MSUD clinical phenotype can be divided into 5 types based on clinical presentation and severity; classical, intermediate, intermittent, thiamine-responsive and E3-deficient forms \[[@bb0005]\].

The BCKDH complex consists of three catalytic components which are organized around a cubic core of 24 identical dihydrolipoamide branched-chain transacylase (E2) that binds to multiple subunits of BCKA dehydrogenase/decarboxylase (E1) and dihydrolipoamide dehydrogenase (E3) \[[@bb0010],[@bb0015]\]. BCKD kinase and mitochondrial-targeted protein phosphatase (PP2Cm) are regulatory enzymes subunits that also attached to the complex. The E1 catalytic component forms as a heterotetramer of E1α and E1β subunits in BCKDH complex \[[@bb0010],[@bb0015]\]. Molecular MSUD genotype has been described in catalytic subunit of BCKDH complex; where for type 1A (OMIM\# [608348](608348){#ir0010}), mutations occurs in *BCKDHA* gene (E1α subunit); for type 1B (OMIM\# [248611](248611){#ir0015}) specifically for mutations found in *BCKDHB* gene (E1β subunit), meanwhile for type II (OMIM\# [248610](248610){#ir0020}), mutations affecting the *DBT* gene (E2 subunit) and type III (OMIM \# [238331](238331){#ir0025}) for mutations occurs in *DLD* gene (E3 subunit) \[[@bb0005]\].

MSUD is known as pan-ethnic disorder and world-wide incidence is very rare, estimated 1:185000. However, in the Mennonites population in Pennsylvania, the incidence is reported to be very high, at 1 in 176 births \[[@bb0005]\]. In Malaysia, inborn error metabolism screening programme successfully detected 25 patients were MSUD and most of the patients occurred in Malay ethnic \[[@bb0020]\].

Molecular genetic testing is essential to facilitate diagnosis and treatment. In addition, information from this testing is important for genetic counseling of the affected family. Genomic alterations that affect BCKDH activity can occur in any of the E1, E2 or E3 subunits, however both alleles at a single gene locus must have mutations \[[@bb0005],[@bb0025]\]. To date, \>283 disease-causing mutations have been described in Human Gene Mutation Database (HGMD) (<http://www.hgmd.cf.ac.uk/ac/index.php>) and scattered over the *BCKDHA*, *BCKDHB* or *DBT* genes. Mutations in *BCKDHA* and *BCKDHB* gene are commonly reported in patients with MSUD compared to *DBT* gene. MSUD patients can be affected either as homozygous or compound heterozygous genotypes. Here, we present the molecular characterization of 31 patients with MSUD by analyzing the *BCKDHA*, *BCKDHB* and *DBT* genes.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

31 patients from 25 unrelated families who attended Metabolic Clinic, Kuala Lumpur Hospital (HKL) were studied. All of them were diagnosed to have MSUD based on clinical presentations and biochemical testing by using quantitative plasma amino acid analysis \[[@bb0020]\]. All patients have been referred to Molecular Diagnostics and Protein Unit (UMDP) for molecular genetic testing. If mutation was detected in the patient, parent samples were requested to analyze the presence of similar mutation in order to test the inheritance cases. Samples from parents were available only for 18 patients and all parents were healthy. 50 healthy unrelated individuals born in Malaysia were also included as control group in this study. Informed consent was acquired from the participants before approximately 5 to 10 ml of peripheral blood was collected in EDTA tubes. This study was approved by the Medical Research and Ethics Committee (MREC) (approval ID: NMRR-12-1321-13062) and it was performed according to the Declaration of Helsinki.

2.2. PCR and sequencing {#s0020}
-----------------------

Genomic DNA of patients and appropriate family members, and also healthy normal control was isolated from a peripheral blood leukocyte using the QIAamp DNA Blood Mini Qiacube Kit (QIAGEN, Hilden, Germany). The touchdown polymerase chain reaction (PCR) method was used to amplify all three genes, *BCKDHA*, *BCKDHB* and *DBT* including intron-exon boundaries \[[@bb0030]\]. All primers were tagged with the universal M13 sequence and detailed description was available upon request. The presence of amplicons with the expected size was run on 1.5% agarose gel under standard electrophoresis parameters.

The QIAquick PCR purification kit (QIAGEN, Hilden, Germany) was used to purify the PCR product and the purified product was subsequently preceded to the cycle sequencing. Big Dye Terminator cycle sequencing version 3.1 (Applied Biosystems, Foster City, CA), was then used to run the bi-directional sequencing while purify cycle sequencing product was carried out using DyeEx 2.0 Spin kit (QIAGEN, Hilden, Germany). Finally, the sequencing reaction was performed on a 48-channel capillary ABI 3730 Genetic Analyzer.

2.3. PCR for large deletion {#s0025}
---------------------------

PCR to detect the large deletion mutations in *BCKDHB* and *DBT* genes were performed by using specific primers. To detect the deletion of Exon 1 in *BCKDHB* gene, specific primers: BCKDHB-1F (forward) 5' GTAAAACGACGGCCAGTGCATTTTAAGGAGGGTGTGAA 3′ and BCKDHB-1R (reverse) 5' GCGGATAACAATTTCACACAGGAATAAGCTGGGATGCAAGGA 3′ were used. While to detect the deletion of Exon 11 in *DBT* gene, specific duplex PCR primers described by Chi and colleagues \[[@bb0035]\] were used. The product was analyzed on 2% agarose gel and visualized by ethidium bromide staining.

2.4. Mutation confirmation {#s0030}
--------------------------

The sequencing results were compared with the genomic reference sequence and coding DNA reference sequence of *BCKDHA* (NC_000019.9 and NM_000709.3), *BCKDHB* (NC_000006.11 and NM_183050.2) and *DBT* (NC_000001.10 and NM_001918.3) using SeqScape Software version 2.5 (Applied Biosystems, Foster City, CA). All reference sequences were retrieved from human genome GRCh37/hg19. Mutation surveyor Software (Softgenetics, State College, PA) was then used to reconfirm the small insertion or deletion mutation. Human Genome Variation Society (HGVS) (<http://www.hgvs.org/mutnomen>) was referred to report the single nucleotide variants (SNVs), insertion and deletion.

The publicly available databases: HGMD \[[@bb0040]\] and 1000G project (<http://www.1000genomes.org>) \[[@bb0045]\] were used for comparison with identified mutations. Meanwhile, in order to rule out a polymorphism, all new mutations were also analyzed with 50 healthy normal individuals (100 alleles). In addition, all new mutations were also compared with variants included in the Genome Aggregation Database (gnomAD) \[[@bb0050]\].

2.5. *In silico* webservers and structure prediction {#s0035}
----------------------------------------------------

Multiple sequence alignments were performed using HomoloGene database (<http://www.ncbi.nlm.nih.gov/homologene>) to verify the degree of conservation. The pathogenicity of the DNA alterations was then evaluated using three *in silico* webservers, PolyPhen2 \[[@bb0055]\], SIFT \[[@bb0060]\] and Mutation Taster2 \[[@bb0065]\]. Mutation Taster2 was also used to predict clinical significant of the splice site, deletion and insertion mutation. The stability/instability of the protein was predicted based on I-Mutant 2.0 server \[[@bb0070]\].

Computational modeling was carried out to observe the effect of new missense mutations on protein structure. Crystal structures for *BCKDHA*, *BCKDHB* and *DBT* proteins were obtained from the protein data bank (RCSB-PDB) \[[@bb0075]\]. Human X-ray crystal structure was only available for *BCKDHA* and *BCKDHB* proteins. Human X-ray (PDB ID: [1X7Y](pdb:1X7Y){#ir0050}) crystal structure with resolution of 1.57 Å was used as a template \[[@bb0080]\]. At the moment, the complete three-dimensional (3D) model of human *DBT* protein was not available in the protein database. Thus, X-ray bovine crystal structure (PDB ID: [2II3](pdb:2II3){#ir0055}) \[[@bb0085]\] with resolution of 2.17 Å was selected as a template. At the moment, only 234 amino acids out of 482 amino acids (from amino acid 188 to 421) of bovine E2 subunit have been crystallized. The 3D structure of target human protein was built using MODELLER 9.9 \[[@bb0090],[@bb0095]\] based on the bovine structure. Generation of mutation plots and visualization of protein effect were performed using PyMOL software \[[@bb0100]\].

3. Results {#s0040}
==========

Thirty-one patients from 25 families were enrolled in this study. Among them, 28 patients (90.3%) were Malays and remaining three (9.7%) were Chinese. Twenty-six (83.9%) patients were clinically diagnosed with the neonatal onset classical form of MSUD, three (9.7%) were intermediate MSUD and two (6.4%) patients were intermittent phenotype. Information on clinical features of all 31 patients is presented in [Table 1](#t0005){ref-type="table"}.Table 1Genotype-phenotype correlation of the 31 patients.Table 1**Family/ \*PatientSexAge of onsetEthnicClinical PhenotypeMutation stateGenetic subtypeExon/ IntronMutationType of MutationGenome number (GRCh37/hg19)Coding DNA numberProtein number**A-1F2yMalayITDHME1αEx-8g. 41928994C \> Tc.1087C \> Tp.R363WMissenseB-1^a^F1yMalayITDHME1αEx-5g.41925082C \> Tc.527C \> Tp.A176VMissenseB-2M1yITDHMC-1F8dMalayCHME1αEx-4g.41920009G \> Ac.431G \> Tp.S144IMissenseD-1M6dMalayCHME1αInt1g.41903846 T \> Cc.108 + 6 T \> Cp.?Splice siteE-1F8dChineseCCHTE1βEx-7g.80910726C \> Tc.818C \> Tp.T273IMissenseEx-10g.81053501C \> Tc.1159C \> Tp.R387\*MissenseF-1M7 mChineseITMCHTE1βEx-3g.80838904G \> Ac.301G \> Ap.G101SMissenseF-2FNSITMCHTEx-5g.80878695T \> Gc.581T \> Gp.L194RMissenseG-1F5dMalayCHME1βEx-9g.80982916C \> Tc.1016C \> Tp.S339LMissenseH-1F6dMalayCCHTE1βEx-1g.80816606G \> Tc.196G \> Tp.G66WMissenseEx-9g.80982916C \> Tc.1016C \> Tp.S339LMissenseI-1^a^F7dMalayCHME1βEx-3g.80838934C \> Tc.331C \> Tp.R111\*NonsenseI-2^b^MNSCHMI-3MNSCHMJ-1F6dMalayCCHTE1βEx-10g.81053436C \> Gc.1094C \> Gp.T365RMissenseEx-10g.81053501C \> Tc.1159C \> Tp.R387\*NonsenseK-1M7dMalayCCHTE1βEx-2g.80837330A \> Gc.263A \> Gp.D88GMissenseEx-9g.80982916C \> Tc.1016C \> Tp.S339LMissenseL-1F5dMalayCCHTE1βEx-7g.80910689T \> Cc.781T \> Cp.S261PMissenseEx-7g.80910710G \> Tc.802G \> Tp.E268\*NonsenseM-1F5dMalayCNAE1β5'UTR-Ex-1g.(80819375_80816718)del\~ 3.3 kb deletion spanning 5'UTR to Exon 1p.?Large deletionN-1M10dMalayCNAE1β5'UTR-Ex-1g.(80819375_80816718)del\~3.3 kb deletion spanning 5'UTR to Exon 1p.?Large deletionO-1M5dMalayCNAE1β5'UTR-Ex-1g.(80819375_80816718)del\~ 3.3 kb deletion spanning 5'UTR to Exon 1p.?Large deletionP-1M4dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseQ-1 ^a^F5dMalayCCHTE2Ex-9g.100672143_100672144insTc.1066_1067insTp.V356Cfs\*3FrameshiftQ-2FNSCCHTEx-11g.100661878C \> Gc.1382C \> Gp.S461\*NonsenseR-1F4dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseS-1M5dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseT-1MNSMalayCCHTE2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseInt1g.100715321C/Tc.51 + 5 G \> CNASplice siteU-1^c^M7dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseU-2^c^M7dCHMV-1M4dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseW-1F6dMalayCHME2Int10--3'UTR Ex-11g.100663570_10066831del4.7-kb deletion flanking parts of intron 10 and the 3'UTR of exon 11p.?Large deletionX-1M8dMalayCCHTE2Ex-9g.100672143_100672144insTc.1066_1067insTp.V356Cfs\*3FrameshiftEx-9g.100672014C \> Gc.1196C \> Gp.S399CMissenseY-1M6dMalayCHME2Ex-9g.100672014C \> Gc.1196C \> Gp.S399CMissense[^1][^2]

3.1. Molecular analysis in *BCKDHA*, *BCKDHB* and *DBT* genes {#s0045}
-------------------------------------------------------------

Molecular analysis successfully revealed that all patients carried mutations on both alleles, with 20 (64.5%) patients were homozygous and 11 (35.5%) patients were compound-heterozygous. [Table 1](#t0005){ref-type="table"} show the *BCKDHB* was found to be the most commonly mutated gene (14 patients, 45%), followed by *DBT* gene (12 patients, 38.7%) and *BCKDHA* gene (5 patients, 16%). The most common mutational types were missense (57%) followed by nonsense mutations (19%), splice site (9.5%), frame-shift (5%) and large deletion (9.5%).

[Table 2](#t0010){ref-type="table"} shows from the total of 21 mutations, 14 were identified as new mutations and not reported previously in HGMD and 1000G project. Meanwhile, 7 mutations have previously been reported in the literature. In order to delineate the pathogenicity of these 14 new mutations, each of them was checked with 50 healthy normal individuals. None of these 14 new mutations were detected in normal population. In addition, 12 new mutations were also not detected in gnomAD database. However not for the other 2 new mutations (T273I and R387\*), which were found as heterozygous state in this database with alleles frequencies were 0.00001628% (4/245752 chromosomes) and 0.00003657% (9/246076 chromosomes), respectively. Missense mutations in *BCKDHA* and *BCKDHB* genes were mapped on the E1α and E1β subunits ([Fig. 1](#f0005){ref-type="fig"}a), while missense mutation in *DBT* gene was mapped on human E2 subunit model ([Fig. 1](#f0005){ref-type="fig"}b).Table 2*In-silico* servers prediction, population frequency, clinical phenotype of patients and co-segregation of the alleles in family.Table 2PatientGenetic subtypeExon/ IntronCoding DNA numberProtein number*In-silico* predictionScreening with 100 normal allelesPopulation allele frequency from gnomAD database (Allele Frequency-%)Clinical phenotypeCo-segregation alleles in familyReferencePolyPhen-2.0SiFTMutation tasterI-MutantGene Conservation in Eukaryota (%)A-1E1αEx-8c.1087C \> Tp.R363W\-\-\-\-\-\--ITDNA\[[@bb0190]\]B-1E1αEx-5c.527C \> Tp.A176VBDDCDec75AAITD1 HM sibling,\
HT mother and HT fatherThis studyC-1E1αEx-4c.431 G \> Tp.S144I\-\-\-\-\-\--CHT mother and HT father\[[@bb0115]\]D-1E1αInt1c.108 + 6 T \> Cp.?\-\-\-\--AACNAThis studyE-1E1βEx-7c.818C \> Tp.T273IPDDDCInc100AP\
\*(1.628 × 10^−5^)CHT fatherBoth mutations detected in gnomAD databaseEx-10c.1159C \> Tp.R387\*\--DC-77AP\
\*(3.657 × 10^−5^)HT motherF-1E1βEx-3c.301G \> Ap.G101SPDDDCDec100AAITM1 CHT siblingThis studyEx-5c.581T \> Gp.L194RPDDDCDec100AAThis studyG-1E1βEx-9c.1016C \> Tp.S339L\-\-\-\-\-\--CHT mother and HT father\[[@bb0195]\]H-1E1βEx-1c.196G \> Tp.G66WPDDDCDec100AACHT fatherThis studyEx-9c.1016C \> Tp.S339L\-\-\-\-\-\--HT mother\[[@bb0195]\]I-3E1βEx-3c.331C \> Tp.R111\*\-\-\-\-\-\--C2 HM siblings,\
HT mother and HT father\[[@bb0145]\]J-1E1βEx-10c.1094C \> Gp.T365RPDDDCInc100AACHT fatherThis studyEx-10c.1159C \> Tp.R387\*\--DC-77AP\
\*(3.657 × 10^−5^)HT motherThis mutation detected in gnomAD databaseK-1E1βEx-2c.263A \> Gp.D88GPDDDCDec88AACNAThis studyEx-9c.1016C \> Tp.S339L\-\-\-\-\-\--\[[@bb0195]\]L-1E1βEx-7c.781T \> Cp.S261PPDDDCInc88AACNAThis studyEx-7c.802G \> Tp.E268\*\--DC-77AAThis studyM-1E1β5'UTR-Ex-1\~ 3.3 kb deletion spanning 5'UTR to Exon 1p.?\-\-\-\-\-\--CNA\[[@bb0140]\]N-1E1β5'UTR-Ex-1\~3.3 kb deletion spanning 5'UTR to Exon 1p.?\-\-\-\-\-\--CNA\[[@bb0140]\]O-1E1β5'UTR-Ex-1\~ 3.3 kb deletion spanning 5'UTR to Exon 1p.?\-\-\-\-\-\--CNA\[[@bb0140]\]P-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT mother and HT fatherThis studyQ-2E2Ex-9c.1066_1067insTp.V356Cfs\*3\--DC-NAAAC1 CHT sibling,\
HT fatherThis studyEx-11c.1382C \> Gp.S461\*\--DC-70AAHT motherThis studyR-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT mother and HT fatherThis studyS-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT mother and HT fatherThis studyT-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT motherThis studyInt1c.51 + 5 G \> CNA\-\-\-\-\-\--HT father\[[@bb0125]\]U-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AAC1 HM sibling,\
HT mother and HT fatherThis studyV-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT mother and HT fatherThis studyW-1E2Int10-3'UTR Ex-114.7-kb deletion flanking parts of intron 10 and the 3'UTR of exon 11p.?\-\-\-\-\-\--CHT mother and HT father\[[@bb0035]\]X-1E2Ex-9c.1066_1067insTp.V356Cfs\*3\--DC\--AACNAThis studyEx-9c.1196C \> Gp.S399CPDDDCDec100AAThis studyY-1E2Ex-9c.1196C \> Gp.S399CPDDDCDec100AACHT mother and HT fatherThis study[^3]Fig. 1(a) The predicted 3D-structure of E1β heterotetramer modified from \[[@bb0085]\] together with the distribution of new missense mutations identified in this study. New missense mutations identified in E1α and E1β subunits are represented by brown and red spheres, respectively. E1α, E1β, E1α' and E1β' are shown in green, wheat, magenta and blue, respectively. The potassium, magnesium and chloride ions are presented in hot-pink, light blue and aquamarine, respectively. Thiamin diphosphates (ThDPs) are shown in yellow stick. The figure was generated with Pymol Version 1.7.4 \[[@bb0100]\]. (b) The predicted 3D-structure of human E2 subunit model together with the new missense mutation. New missense mutation identified is represented by yellow sphere. E2 subunit is shown in purple and CoA-enzyme in green stick. The figure was generated with Pymol Version 1.7.4 \[[@bb0100]\]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

3.2. *In silico* prediction and structural analysis for new mutations {#s0050}
---------------------------------------------------------------------

### 3.2.1. *BCKDHA* gene {#s0055}

One missense mutation was identified, leading to the amino acid change p.A176V. According to multiple sequence alignment analysis, A176 was 75% conserved among the species. 2 (SiFT and Mutation taster) out of 3 *in silico* servers predicted substitution from alanine to valine was disease-causing ([Table 2](#t0010){ref-type="table"}). Meanwhile, PolyPhen server predicted this mutation as benign. Structural analysis exhibited A176 was located on the α-helix 5 of the α-subunit, near to the β-subunit. The backbone nitrogen of A176 was observed to form hydrogen bond interaction with backbone carbonyl oxygen of E172. Meanwhile, the carbonyl oxygen of A176 formed hydrogen bond interaction to backbone nitrogen of G180 and N181. The substituted V176 however did not alter the hydrogen bond interactions with their neighboring residues ([Fig. 2](#f0010){ref-type="fig"}a). However, I-Mutant server predicted this mutation affect the stability of the structure. Another new mutation was located near to splice donor site (c.108 + 6 T \> C) and Mutation Taster webserver predicted this mutation was disease-causing.Fig. 2Structural illustration of the new missense mutations in E1b heterotetramer. a) New missense mutation in α subunit. b-h) New missense mutations in β subunit. Wild-type residue is in yellow sticks while mutated residue is in cyan sticks. Hydrogen bonds are denoted by black dotted lines. E1α, E1β, E1α' and E1β' are shown in green, wheat, magenta and blue, respectively. The potassium, magnesium and chloride ions are presented in hotpink, light blue and aquamarine, respectively. Thiamin diphosphates (ThDPs) are shown in yellow stick. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

### 3.2.2. *BCKDHB* gene {#s0060}

Two new nonsense (p.E268\* and p.R387\*) and 6 new missense (p.G66 W, p.D88G, p.G101S, p.L194R, p.S261P, p.T273I and p.T365R) mutations were identified and scattered in exons 1, 2, 3, 5, 7, 9 and 10 ([Table 2](#t0010){ref-type="table"}). All nonsense and missense mutations showed high evolutionary conservation across orthologous E1β subunits (77% to 100%). Further *in silico* analyses predicted that all missense mutations in this gene were damaging to the protein function ([Table 2](#t0010){ref-type="table"}).

Mutation p.G66W is located on the N-terminal domain of β subunit. Residue G66 was substituted by the larger and more hydrophobic tryptophan. However, we observed side chain of wild type (G66) and mutant (W66) did not form intramolecular interactions within the protein structure ([Fig. 2](#f0010){ref-type="fig"}b). Mutation p.D88G is located on the protein surface. Residue D88 formed hydrogen bond interaction to 4 neighboring residues (S84, T90, A91 and T142), however the substituted G88 exhibited loss of interactions to T90 and T142 ([Fig. 2](#f0010){ref-type="fig"}c). Mutation p.G101S is also located on the protein surface. Although both amino acids are classified in similar aliphatic group, neutral and hydrophilic, this substitution could affect the formation of hydrogen bond with surrounding residues ([Fig. 2](#f0010){ref-type="fig"}d). We observed the substituted S101 formed an additional interaction with F100. Another new missense mutation, p.L194R is located within loop and interfaces with β, β′ and α′ subunits. We observed the wild type (L194) and mutant (R194) formed hydrogen bond interaction to similar side chain of residue, Q198 ([Fig. 2](#f0010){ref-type="fig"}e).

Mutation p.S261P is located within and interfaces with α subunit. The replacement of hydrophilic serine to hydrophobic proline caused loss of hydrogen bond interactions to residues, T306 and P309 ([Fig. 2](#f0010){ref-type="fig"}f). Another mutation, p.T273I is located in beta strand. The T273 was observed to form hydrogen bond interactions to 4 neighboring residues (S318, T322, R324 and L326). However, the substituted I273 caused loss of interactions with 2 neighboring residues (S318 and T322) ([Fig. 2](#f0010){ref-type="fig"}g). Mutation at position 365 caused a change of threonine to arginine (p.T365R). Residue T365 is located on the C-terminal domain of β and interfaces with α' subunit, and was observed to form hydrogen bond interactions to Y363 and P366. However, the substituted R365 caused loss of hydrogen bond interaction to P366 and at the same time, it formed a new interaction with L413 from α′ subunit ([Fig. 2](#f0010){ref-type="fig"}h).

### 3.2.3. *DBT* gene {#s0065}

The E2b subunits of BCKDC contains an N-terminal lipoyl-bearing domain (LBD), an internal subunit-binding domain (SBD) and a C-terminal core (catalytic) domain (E2bCD) \[[@bb0105],[@bb0110]\] . Taking into account the protein sequence of bovine shares 93% identity with human homology and the identified mutation occurs in E2bCD domain, the bovine protein structure was used as a model to study the effects of MSUD mutation in human.

Three new mutations were identified. Nonsense (p.S461\*) and frameshift (p.V356CfsX3) mutations found in exons 11 and 9, respectively, were considered to be disease causing due to creation of premature termination codon. New missense mutation p.C399S was found in exon 9. *In silico* analysis predicted this mutation was damaging to the protein function. Structure analysis exhibited both amino acids, serine and cysteine consisted a very similar form of backbone structure but differed in the side chains; serine consisted a hydroxyl side chain while cysteine consisted a sulfhydryl side chain. Side chain of serine formed interaction with a CoA-enzyme ligand, however the substituted C399 was observed to cause loss of interaction to this ligand ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Structural analysis for new missense mutation in human E2 subunit model. The E2 subunit is shown in green transparency cartoon. Wild-type residue is in yellow sticks while mutated residue is in cyan sticks. CoA-enzyme (CoA) is shown in orange stick. Hydrogen bonds are denoted by black dotted lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

4. Discussion {#s0070}
=============

To the best of our knowledge, only one mutation in patients with MSUD has been reported in Malaysia \[[@bb0115]\]. Here, we presented the first comprehensive study of MSUD mutational spectrum for Malaysia population. *T*he present study revealed MSUD was predominant among the Malay ethnic (90.3%). Both *BCKDHB* (45.2%) and *DBT* (38.7%) genes were the most frequent mutated genes in our patient cohort. The finding is in contrary to other studies, in which the most commonly affected genes are being either *BCKDHA* or *BCKDHB* \[[@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140]\]. This indicates possibility of *BCKDHB* and *DBT* being the common genes for MSUD in Malaysia population. Therefore, for future molecular screening, especially for Malay ethnic, both genes can be suggested to be proceeded first.

To date, approximately 280 mutations have been reported in HGMD. *BCKDHB* gene has been described as the major gene causing MSUD, followed by *BCKDHA* gene and *DBT* gene \[[@bb0040]\]. In this study, 21 different mutations have been detected and scattered in three genes, confirming the heterogenous distribution of mutations in this disease. 57% of the mutations were accounted to *BCKDHB* gene and the other half was distributed closely between *BCKDHA* (19%) and *DBT* (24%) genes. However, this is contrast with the previous literatures that highlight frequency mutation in *BCKDHA* and *BCKDHB* genes is observed to be equal \[[@bb0120],[@bb0135],[@bb0145]\].

The current study showed 14 out of 21 mutations were identified as new. A new c.1196C \> G (p.S399C) genotype was the most frequent in our samples (16 out of 62 alleles), detected as homozygous and heterozygous in 7 (Patient: P-1, R-1, S-1, U-1 and U-2, V-1, and Y-1) and 2 (Patient: T-1 and X-1) patients, respectively. All patients with this mutation were found to be having MSUD classical phenotype. The p.S399C was predicted to be disease-associated by four *in silico* webservers. In human E2 structure model, residue S399 is corresponding to residue S338 on the bovine E2bCD crystal structure. Residue S338 was located in ligand binding pocket and was found to form hydrogen bond with a peptide nitrogen atom in the pantetheine tail of CoA-enzyme ligand \[[@bb0085]\]. However, in the present study, substitution from serine to cysteine caused loss of interaction with CoA-enzyme ligand, thus possibly leading to destabilization of the binding pocket of E2 subunit protein structure. In addition, residue S338 was proposed to be involved in the acetyltransfer reaction presumably through stabilization of the tetrahedral intermediate \[[@bb0150]\]. It is therefore possible this mutation could affect the formation of tetrahedral intermediate interaction and subsequently gives an impact to the catalytic activity of the complex. Meanwhile, the serine residue at this position was highly conserved and therefore changes to cysteine or other amino acids were predicted to be pathogenic.

Currently, founder mutations in *DBT* gene were reported in Filipino population (a 239-bp insertion after exon 10) \[[@bb0155]\] and in general population of Paiwan Austronesian Aboriginal tribe in southern Taiwan (4.7-kb deletion of intron 10) \[[@bb0035]\]. Founder mutations are also remarked in *BCKDHA* and *BCKDHB* genes and identified in 3 different populations; (1) c.1312 T \> A (p.Y438N) found in *BCKDHA* gene is associated in Mennonite populations in US \[[@bb0160]\], (2) Portuguese Gypsy has been reported to harbor c.117delC (p.R40GfsX23) in *BCKDHA* gene \[[@bb0165]\] and (3) c. 538G \> C (p.R183P) mutation in *BCKDHB* gene is discovered in Ashkenazi Jewish population \[[@bb0170]\]. In the current study, this new missense mutation p.S399C was predominantly observed in Malay ethnic. However, we were unable to run haplotype analysis to justify this mutation as founder effect in our population, but we have identified this mutation was absent in 100 normal control alleles and also in gnomAD database. Therefore, we assumed this mutation would be a common and unique to Malay community in Malaysia population.

The heterozygous genotypes for new missense mutations in *BCKDHB* gene; c.301G\>A (p.G101S), c.581 T\>G (p.L194R), c.196G\>T (p.G66W), c.1094C\>G (p.T365R), c.263A\>G (p.D88G) and c.781T\>C (p.S261P) were suggested as very rare variant in general population as it was not detected in our 100 normal control alleles and also in gnomAD database. For another missense mutation, c.818C\>T (p.T273I), although it was found in gnomAD database, but it was not detected in homozygous state and the alleles frequency was very low (MAF \<1/10,000). Furthermore, a homozygous missense mutation at the same position (p.T273P) has previously been reported in Saudi Arabia patient with intermediate phenotype \[[@bb0175]\]. Therefore, this variant can also be considered as a rare in the general population.

Structure observation showed missense mutations, p.T273I, p.G101S, p.G66W, p.T365R, p.D88G and p.S261P were possibly leading to destabilization of E1b structure \[[@bb0015]\]. For mutation p.L194R, although did not affect the surrounding hydrogen bond interaction but it was discovered as compound heterozygous which formed along with new missense mutation, p.G101S. The p.G101S was observed to cause an effect to the E1b protein structure due to formation of extra hydrogen bond with the surrounding residue. Therefore, both mutations were predicted to indirectly affect the E1b structure. Furthermore, both mutations segregated in family F, where 2 patients were affected (Patient F-1 and Patient F-2) with a compound heterozygous, while their parents were heterozygous. Further analysis by *in silico* servers predicted all missense mutations in *BCKDHB* gene were pathogenic. Meanwhile, these mutations affect the highly conserved residue, further confirming pathogenicity. Clinical presentations in all affected patients were an evidence, which all patients suffered from classic and intermittent forms of the disease.

A homozygous genotype for a new missense mutation c.527 C\>T (p.A176V) in *BCKDHA* gene was found in family B. Although one *in silico* server predicted this new mutation as benign, however, this mutation segregated in this family, in which 2 patients were affected with homozygous genotype. Both affected patients had MSUD intermediate phenotype. In addition, this mutation was not found in HGMD and 1000G project databases. This mutation was also not detected in our 100 normal control alleles and in gnomAD database, suggesting this mutation was very rare in general population. Another new homozygous genotype in *BCKDHA* gene was detected as splice site c.108 + 6 T \> C. However, the pathogenicity of this mutation could not be validated due to no RNA sample. Nevertheless, analysis by *in silico* server to this intronic variant was predicted to eliminate the respective donor site. It is expected that this mutation would produce unstable mRNA and hence leading to production of a protein with null effect \[[@bb0180],[@bb0185]\]. Furthermore, this mutation was not presented in our 100 normal control alleles and also not discovered in gnomAD database, suggesting this mutation was very rare in general population. Clinical presentation in Patient-D1 was an evidence, in which he was suffered from classic form of the disease.

Three heterozygous genotypes for new nonsense mutations were discovered; 2 in *BCKDHB* gene, c.802G \> T (p.E268\*) and c.1159C \> T (p.R387\*) and 1 in *DBT* gene c.1382C \> G (p.S461\*). In addition, one new frame shift mutation was found in *DBT* gene c.1066_1067insT (p.V356Cfs\*3). The p.E268\*, p.S461\* and p.V356Cfs\*3 were suggested very rare variants in general population as those variants were not presented in our 100 normal control alleles and also in gnomAD database. The p.R387\* was discovered in gnoMAD database, however the alleles frequency was very low when compared to the world-wide incidence rate. In addition, this mutation was not found in homozygous state, implying this mutation was a rare in the general population. The nonsense and frame shift mutations were predicted to be pathogenic as those mutations resulted to code for stop codon in the transcribed mRNA and possibly caused an effect in formation of the normal protein function. Furthermore, all nonsense and frame shift mutations were predicted to be disease causing by *in silico* server, further confirming the pathogenicity. The effects of these mutations were consistent with the clinical presentation in all patients, in which the patients have MSUD classical phenotype.

5. Conclusion {#s0075}
=============

In conclusion, 21 different mutations were identified in *BCKDHA*, *BCKDHB* and *DBT* genes from 31 patients. Fourteen were new mutations and scattered along the E1α, E1β, and E2 subunits. All new mutations were predicted to potentially destabilize formation of the E1 and E2 complexes. Interestingly, mutation in *DBT* gene, c.1196C \> G (S399C) was discovered to be as recurrent mutation and commonly found in Malay community. Therefore, our study expands the mutation spectrum of MSUD and finding of recurrent mutation is important for disease management and genetic counseling for Malaysia population.
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[^1]: Abbreviations: ^a^ = sister, ^b^ = brother, ^c^ = Twins, F = female, M = Male, y = years, d = day, m = month, NS = neonatal screening, ITD = Intermediate, C = Classical, ITM = Intermittent, HM = homozygous, CHT = compound heterozygous, NA = not applicable.

[^2]: Samples from parents were available for B, C, E, F, G, H, I, J, P, Q, R, S, T, U, V, W and Y.

[^3]: - = not calculable, B = Benign, PD = Probably damaging, D = Damaging, DC = Disease causing, Dec = Decrease, Inc. = Increase, A = Absence; P = Presence, \* = This variant is \<1/10000, ITD = Intermediate, C = Classical, ITM = Intermittent, HM = Homozygous, CHT = Compound heterozygous, HT = Heterozygous, NA = Not applicable.
